Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan

Liu, Hsi‐Che; Kuo, Ming‐Chung; Wu, Kang‐Hsi; Chen, Tsai-Yun; Chen, Jiann‐Shiuh; Wang, Ming-Chung; Lin, Tsan-Shiun; Yang, Youngsen; Ma, Ming‐Chun; Wang, Po‐Nan; Sheen, Jiunn‐Ming; Wang, Shih-Chung; Chen, Shih-Hsiang; Jaing, Tang‐Her; Cheng, Chao‐Neng; Yeh, Ting‐Chi; Lin, Te-Hsien; Shih, Lee‐Yung

doi:10.1038/s41416-023-02162-9

Cited by 2 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As evident from data on adult CML and TKI use, some toxicities might appear early on in the course of treatment and improve over time, whereas many toxicities may appear after years and be of more clinical significance. This include but are not limited to pleural effusions and vascular events (38). Growth restriction of deceleration represent a critical area of concern for potential long-term adverse effects in pediatric CML, a phenomenon less likely to manifest in adult populations.…”

Section: Safety Of Tkis In Pediatric CMLmentioning

confidence: 99%

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials

Ata,

Benkhadra,

Ghasoub

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Tyrosine Kinase Inhibitors (TKIs) is revolutionizing the management of pediatric Chronic Myeloid Leukemia (CML), offering alternatives to Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). We conducted a comprehensive review of 16 Randomized Controlled Trials (RCTs) encompassing 887 pediatric CML patients treated with TKIs including Imatinib, Dasatinib, and Nilotinib. The median patient age ranged from 6.5 to 14 years, with a median white blood cell count of 234 x 10^9/uL, median hemoglobin level of 9.05 g/dL, and median platelet count of 431.5 x 10^9/µL. Imatinib seems to be predominant first line TKI, with the most extensive safety and efficacy data. BCR::ABL response rates below 10% ranged from 60% to 78%, CCyR at 24 months ranged from 62% to 94%, and PFS showed variability from 56.8% to 100%, albeit with differing analysis timepoints. The Safety profile of TKIs was consistent with the known safety profile in adults. With the availability of three TKIs as first line options, multiple factors should be considered when selecting first line TKI, including drug formulation, administration, comorbidities, and financial issues. Careful monitoring of adverse events, especially in growing children, should be considered in long term follow-up clinical trials.

show abstract

Section: Safety Of Tkis In Pediatric CMLmentioning

confidence: 99%